Opus Genetics, Inc. (IRD) Stock

Opus Genetics, Inc. (IRD) is a Healthcare stock trading at $4.07 (as of 2026-06-18), with a market capitalization of $354.88M and a trailing P/E of -3.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing and commercializing treatments for unmet needs in patients with refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution for reversal of mydriasis, a Phase III program for presbyopia and dim light/night vision disturbances, and retinal product candidates such as APX3330 plus earlier-stage candidates APX2009 and APX2014.

Valuation — source: SEC EDGAR (first-party)
Price	$4.07
Market Cap	$354.88M
P/E Ratio	-3.1
EV / EBITDA	-6.3
Price / Book	-7.23
Price / Sales	27.65
DCF Value (model)	$-7.82
DCF Upside vs Price	-292.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$14.20M
Net Margin	-349.3%
Return on Equity	233.3%
Debt / Equity	-0.03
Current Ratio	7.13
Revenue Growth (YoY)	29.1%
EPS Growth (YoY)	-62.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.52 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-114.9%
vs Industry	-118.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Caligan Partners LP ($27.64M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	George Magrath
Employees	18
Country	US
IPO Date	2015-01-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.